Impact Factor 3.508
2017 JCR, Clarivate Analytics 2018

Frontiers journals are at the top of citation and impact metrics

Frontiers in Neurology

Neurodegeneration

This article is part of the Research Topic

Biomarkers in Neurology

Systematic Review ARTICLE Provisionally accepted The full-text will be published soon. Notify me

Front. Neurol. | doi: 10.3389/fneur.2019.00290

Association between aldehyde dehydrogenase-2 polymorphisms and risk of Alzheimer’s disease and Parkinson’s disease: A meta-analysis based on 5,315 individuals

Jun Chen1, Wei Huang1, Chao-Hui Cheng1,  Lan Zhou1*, Guang-Bin Jiang2 and  Yuan Y. Hu1
  • 1Department of Neurology, Taihe Hospital, Hubei University of Medicine, China
  • 2Department of Radiology, Suizhou Central Hospital, China

Objective: A number of studies have reported that aldehyde dehydrogenase-2 (ALDH2) polymorphisms maybe associated with the risk of Alzheimer’s disease (AD) and Parkinson’s disease (PD). However, the results of such studies are inconsistent. We therefore conducted a meta-analysis to clarify the association between ALDH2 polymorphisms and the risk of AD and PD.
Methods: Five online databases were searched and the relevant studies were reviewed from inception through May 10, 2018. Odds ratios (ORs) and corresponding 95% confidence intervals (CIs) were calculated in each genetic model of the general population and various subgroups. Furthermore, we simultaneously performed heterogeneity, cumulative, sensitivity, and publication bias analyses.
Results: Overall, nine case-control studies involving 5,315 subjects were included in this meta-analysis. Potential associations were found between the ALDH2 rs671 G>A polymorphism and the risk of AD (A vs. G: OR=1.46, 95%CI=1.01-2.11, P=0.05, I2=84.2%; AA vs. GG: OR=2.22, 95%CI=1.03-4.77, P=0.04, I2=79.2%; AA vs. GG+GA: OR=1.94, 95%CI=1.03-3.64, P=0.04, I2=71.1%). In addition, some similar results were observed in other subgroups. Moreover, no significant association between ALDH2 polymorphisms and PD risk.
Conclusions: In conclusion, our meta-analysis indicated that the ALDH2 rs671 G>A polymorphism plays an important role in AD development.

Keywords: Aldehyde Dehydrogenase 2, Neurodegenerative disorders, Alzheimer’s disease, Parkinson’s disease, polymorphism

Received: 04 Oct 2018; Accepted: 06 Mar 2019.

Edited by:

Mohamed M. Salama, Mansoura University, Egypt

Reviewed by:

Maria Shadrina, Institute of Molecular Genetics (RAS), Russia
Petr A. Slominsky, Institute of Molecular Genetics (RAS), Russia  

Copyright: © 2019 Chen, Huang, Cheng, Zhou, Jiang and Hu. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

* Correspondence: Prof. Lan Zhou, Taihe Hospital, Hubei University of Medicine, Department of Neurology, Shiyan, Hubei Province, China, 1902764052@qq.com